Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Prostate Cancer
NCT05803941Phase 4Recruiting
- Sponsor
- Novartis
- Start
- Aug 2023
- Primary completion
- Jul 2033
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 11
01
Overview
A Phase 4 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Novartis. Started Aug 2023; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05803941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803941.